Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post
Liffert Vogt1, Sripal Bangalore2, Rana Fayyad3
11 Department of Internal Medicine Amsterdam Cardiovascular Sciences Amsterdam University Medical Centre University of Amsterdam The Netherlands.
Insights
Atorvastatin improved kidney function in a dose-dependent manner for patients with cardiovascular disease. This kidney function improvement was linked to reduced cardiovascular risk across all treatment groups.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Kidney function decline is a significant predictor of kidney and cardiovascular outcomes.
- Statins are known to reduce cardiovascular risk, potentially through effects on kidney function.
Purpose of the Study:
- To investigate the effect of atorvastatin on kidney function decline.
- To assess the association between kidney function changes and cardiovascular outcomes.
Main Methods:
- Analysis of data from 30,621 patients across 6 large atorvastatin cardiovascular outcome trials.
- Mixed-model analyses were used to determine slopes of serum creatinine reciprocals, representing kidney function change.
- Patients were categorized into placebo, atorvastatin 10 mg, and atorvastatin 80 mg groups.
Main Results:
- Kidney function showed linear improvement over time in all treatment groups.
- Atorvastatin demonstrated a dose-dependent improvement in kidney function (0.009 placebo, 0.011 10 mg, 0.014 80 mg [mg/dL]⁻¹/y).
- A significant negative association was found between kidney function improvement and cardiovascular outcomes (P<0.0001).
Conclusions:
- Atorvastatin improves kidney function over time in a dose-dependent manner in patients at risk for or with cardiovascular disease.
- Improved kidney function in patients treated with atorvastatin is strongly associated with a lower risk of cardiovascular events.
Abstract:
Background Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. Methods and Results Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL]-1/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed-model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)-1/y, respectively. A head-to-head comparison of atorvastatin 10 and 80 mg based on data from 1 study ( TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope between the 2 doses ( P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant ( P<0.0001) negative association between kidney function and cardiovascular outcomes was found. Conclusions In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose-dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifiers: NCT00327418; NCT00147602; NCT00327691.
Related Concept Videos
Blind Procedures
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Blinding
Statistical Software for Data Analysis and Clinical Trials
Transfer Function in Control Systems
To derive the transfer function, consider a general nth-order linear time-invariant...
Kidney Structure

